中文 English
联系我们|隐私条款|站点地图|注册|登录
 
 
福建坤彩材料科技股份有限公司在欧洲设立办事处

Fujian Kuncai Material Technology Co., Ltd. (Kuncai), based in Fuqing, Fujian province, China, a world player in the field of pearlescent pigments, has started its own marketing-sales office in Europe under the name Kuncai Europe B.V.

Kuncai has formed a joint venture in Europe with partner QolorTech B.V., a marketing and sales company in the Netherlands with a long history in pigments. The QolorTech sales and technical staff, responsible for effect pigments, has joined the new company. Kuncai Europe is based in Vaassen, the Netherlands and is a total service company with a prime focus on the European market and Turkish market.

“By combining the unique quality of the Kuncai pearls and our knowledge of the European market in this new sales organization, we will sustain the strong growth scenario of Kuncai in Europe”, said Michiel de Jong, Managing Director of Kuncai Europe.

Kuncai is one of the largest producers of pearl pigments in the world and offers a wide variety of pigments based on natural mica, synthetic mica and borosilicate for Automotive, Coatings, Plastics, Inks and Cosmetics. The construction of an additional production plant is in progress, boosting the capacity towards 40.000 tonnes.

Kuncai Europe will manage the marketing/sales of the full product range into the European and Turkish market. For technical support, a fully equipped service laboratory is in place in Vaassen. The marketing/sales team is managed by Arrie ten Caat who has been a leading figure in the pearl pigment market for the last 25 years. The technical sales staff is to be expanded in the course of 2015.




 
 
中国化工集团公司收购克劳斯玛菲集团

China’s leading chemicals group, China National Chemical Corporation (“ChemChina”), has agreed to acquire KraussMaffei Group from Onex Corporation for a cash enterprise value of EUR 925 million. The transaction is subject to closing conditions including customary regulatory approvals. The transaction is expected to accelerate the growth of the company considerably in light of potential business synergies. ChemChina will make this acquisition together with Guoxin International Investment Corporation and Agic Capital.

“With ChemChina, we have found a strategic and long-term oriented investor who has been interested in our company for many years,” said Frank Stieler, CEO of the KraussMaffei Group. The KraussMaffei Group will continue to operate in its current corporate structure. In early 2013, the Canadian venture capital company Onex took over KraussMaffei from the then-owner Madison Capital for EUR 568 million.

Ting Cai, Chairman and CEO of the China National Chemical Equipment Co. Ltd. (CNCE), Dr. Frank Stieler, CEO of the KraussMaffei Group, and Chen Junwei, CEO of the ChemChina Finance Co. Ltd. (from left, © KraussMaffei)

“We are strengthening our company with one of the leading global engineering groups, encompassing a 178-year corporate history. In doing so, we expect that KraussMaffei Group will maintain its identity and independence,” said Jianxin Ren, Chairman of ChemChina. “We are investing in the Company’s strong management team and its technological expertise, which we believe will benefit our Chinese subsidiaries and position the chemical machinery business of ChemChina, which build and sell equipment for the rubber and chemical industry, to become a pioneer in achieving the “Made in China 2025” program which aims to enhance Chinese industry. The growth potential of the KraussMaffei Group is tremendous, especially through improved access to the Chinese market, which we can make possible. We expect trends in the automotive industry towards advanced manufacturing and lightweight components will provide a huge development opportunity for the high-end plastic injection molding industry. Together, ChemChina and the KraussMaffei Group will be well positioned for future growth,” added Jianxin Ren.

Locations Remain

In China, KraussMaffei is expected to benefit in particular from the trend towards higher quality and sustainability. The machines and systems of the three brands - KraussMaffei, KraussMaffei Berstorff and Netstal - are especially suited to meet more challenging customer requirements. As a result of the transaction, the KraussMaffei Group will be able to accelerate its planned expansion in China. The KraussMaffei Group’s headquarters will remain in Munich and the operating and corporate responsibility for the company will stay in Europe. This applies in particular to production, technology, patents as well as research and development. The KraussMaffei Group will continue to operate as a German company with a Supervisory Board based on co-determination. All existing collective agreements and location-based commitments will remain unchanged. At present, the company has approximately 4,500 employees globally, of which 2,800 are based in Germany. The company intends to increase its workforce in 2016, including in Germany.

ChemChina is China’s largest chemicals group, having generated revenues of around EUR 37 billion in 2015 with approximately 140,000 employees, of whom 45,000 are located outside China. The group operates internationally and has a global expansion strategy, having acquired or invested in companies in Italy, France, Norway, the UK and Singapore in the last few years with the most recent acquisition being the high-end tire manufacturer Pirelli. Following Onex’s acquisition KraussMaffei Group has demonstrated sustained improvement in its financial and operational performance. In 2014, the Company generated revenues of approximately EUR 1.1 billion and is expected to achieve year-on-year revenue growth of approximately 10 % for 2015. According to Onex KraussMaffei lastly achieved annual earnings (Ebitda) of EUR 140 million.

The employee representatives and IG Metall welcome the planned change in ownership. “We consider the transaction as a significant opportunity for the KraussMaffei Group and its employees. We are confident that through further growth the existing jobs in Germany and Europe will be secured and expanded,” commented Peter Krahl, Chairman of the works council of the KraussMaffei Group.




 
 
赢创扩大创业投资活动进入亚洲

By investing in the Chinese venture capital fund GRC SinoGreen Fund III (GRC III), Evonik Industries AG, Essen, Germany, has expanded its venture capital activities into Asia. The parties have agreed to not disclose the amount of the investment. As a result, the company is now represented in the most important venture capital regions of North America, Europe, and Asia.

GRC invests in private, green technology companies with unique strengths and substantial growth potential in Greater China. Target sectors include energy and resource efficiency, cleaner transportation, sustainability, and climate change mitigation and adaptation. GRC III has offices in Beijing and Taipei. In recent years, Asia has evolved into the world’s third-most important venture capital region. China accounts for around two-thirds of these activities.

"By investing in GRC III, we are opening the door to the fast growing start-up community in Greater China," explained Bernhard Mohr, head of Venture Capital at Evonik. "With GRC we have found a strong partner with a proven track record and with immediate relevance to our own business activities." As part of its venture capital activities, Evonik plans to invest a total of €100 million in promising start-ups with innovative technologies and in leading specialized venture capital funds. The regional focus is on Europe, the US, and Asia. Evonik currently has holdings in eight start-ups and four funds.




 
 
赢创扩大创业投资活动进入亚洲

By investing in the Chinese venture capital fund GRC SinoGreen Fund III (GRC III), Evonik Industries AG, Essen, Germany, has expanded its venture capital activities into Asia. The parties have agreed to not disclose the amount of the investment. As a result, the company is now represented in the most important venture capital regions of North America, Europe, and Asia.

GRC invests in private, green technology companies with unique strengths and substantial growth potential in Greater China. Target sectors include energy and resource efficiency, cleaner transportation, sustainability, and climate change mitigation and adaptation. GRC III has offices in Beijing and Taipei. In recent years, Asia has evolved into the world’s third-most important venture capital region. China accounts for around two-thirds of these activities.

"By investing in GRC III, we are opening the door to the fast growing start-up community in Greater China," explained Bernhard Mohr, head of Venture Capital at Evonik. "With GRC we have found a strong partner with a proven track record and with immediate relevance to our own business activities." As part of its venture capital activities, Evonik plans to invest a total of €100 million in promising start-ups with innovative technologies and in leading specialized venture capital funds. The regional focus is on Europe, the US, and Asia. Evonik currently has holdings in eight start-ups and four funds.




 
 
在中国国际橡塑展医用塑料

At Chinaplas many different types of medical plastics exhibits will be displayed (© Adsale Exhibition Services)

Chinaplas will launch its 30th edition on April 25-28, 2016 at Shanghai New International Expo Centre, PR China. With immensely positive audience feedback in the last edition, the Medical Plastics Conference will stage its 2nd edition at the fairground on April 25 and 26 to share high-end technology and remarkable insights, and demonstrate how medical plastics technology drives the innovation of the medical industry.

At the conference, Shanghai MicroPort Medical (Group) Co., Ltd. will share "The Technology of Precision Medical Polymer Tube for Invasive Medical Device". Precision medical tubes are widely used in invasive medical devices, and their properties will determine the performance of these invasive devices. The presentation will introduce the technologies in producing precision medical polymer tube, which are critical in deciding their properties.

Among others, Stefania Marconi, Biomedical Engineer, PhD in Experimental Surgery and Microsurgery from the University of Pavia, Italy, will discuss about "Plastic Materials in 3-D Printing: Surgical Planning and Clinical Applications". Her presentation will focus on standard plastic materials to high-resolution photopolymers to biocompatible materials, the applications of 3-D printing on anatomical prototyping for surgical planning, and 3-D printing of biocompatible implants.

The medical plastics and processing technologies tailor-made for medical industry keep on developing. This enhances the production efficiency and product quality of medical devices and disposable medical products, responding to the growing market demand and creating numerous business opportunities. In addition to the Medical Plastics Conference, Chinaplas 2016 will also exhibit a variety of medical plastics, molds for medical supplies and injection molding technology for the production of petri dish. 







     
  上页   1   2   3   4   下页  
     
  发送给朋友| 打印友好
卡尔翰思出版社
Kolbergerstrasse 22 • 81679 Munich, Germany
Tel:+49 (0) 89 / 998 30-271 Fax:+49 (0) 89 / 998 30-269
Email:sales(at)hanser.de 隐私条款
版权 2014 © 翰思 (Hanser) 出版社 京ICP备09021026号